5 Best Guru Stocks To Buy Now

3. Ascendis Pharma A/S (NASDAQ:ASND)

Number of Hedge Fund Holders: 26

Percentage of Guru Index ETF’s Net Assets as of October 18: 1.72%

Ascendis Pharma A/S (NASDAQ:ASND) is a Denmark-based biopharmaceutical company, focused on developing therapeutics for unmet medical needs. Guru owns 6,966 shares of Ascendis Pharma A/S (NASDAQ:ASND) as of October 18, worth $781.5 million and representing 1.72% of the total portfolio. Ascendis Pharma A/S (NASDAQ:ASND) is one of the premier Guru stocks to buy now. 

On October 10, Citi analyst David Lebowitz opened a “90-day upside Catalyst Watch” on Ascendis Pharma A/S (NASDAQ:ASND), relating to upcoming top line data for TransCon CNP for the treatment of achondroplasia from the Phase II ACcomplisH trial. The analyst believes positive data would be a “significant catalyst for shares, leading to double digit upside.”

According to Insider Monkey’s data, 26 hedge funds were bullish on Ascendis Pharma A/S (NASDAQ:ASND) at the end of the second quarter of 2022, compared to 28 funds in the last quarter. Peter Kolchinsky’s RA Capital Management is the leading position holder in the company, with 7.6 million shares worth $703.5 million. 

Here is what Artisan Partners specifically said about Ascendis Pharma A/S (NASDAQ:ASND) in its Q2 2022 investor letter:

“Sales for Ascendis Pharma A/S (NASDAQ:ASND)’s recently approved pediatric growth hormone drug, Skytrofa, came in below expectations despite solid prescription volume. Patients are either on the free version of the drug, or they are finishing their current supply before starting treatment. Longer term, we are optimistic the company will convert free Skytrofa patients to the commercial reimbursed product. Furthermore, we anticipate TransCon PTH, used to treat hyperparathyroidism, will be approved and rolled out in 2023, providing another tailwind to the company’s profit cycle.”